Skip to main navigation Skip to search Skip to main content

A Phase 3, Randomized, Double-Blind, Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

  • Briggs, Peter (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date17/11/21 → 16/11/26

Keywords

  • treatment safety
  • treatment efficacy
  • phase 3 study
  • lung cancer

Clinical Trial Phase

  • Phase III (a & b)